Drug recall
IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only…
FDA recall event 89876 · Class I · Teva Pharmaceuticals USA Inc
Key facts
| Event ID | 89876 |
|---|---|
| Recall numbers | D-0765-2022 |
| Recalling firm | Teva Pharmaceuticals USA Inc |
| Product type | Drugs |
| Products | IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11. |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary: Firm Initiated |
| Reason for recall | Presence of Particulate Matter: Product was found to contain silica and iron oxide |
| Initiation date | Mar 29, 2022 |
| Report date | Apr 20, 2022 |
| Termination date | Jun 20, 2023 |
| City | Parsippany |
| State | NJ |
| Country | United States |
| FEI number | 3003092769 |
At a glance
- 1–9 Products in this recall
- 1–9 FDA inspections of this firm (FEI)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug and product recalls
FDA enforcement reports list recalls of drugs, biologics, foods and other FDA-regulated products, classified by the potential health hazard.
Source: U.S. Food and Drug Administration (FDA), Enforcement Reports · Source date: